Takeda Announces China NMPA Approval of LIVTENCITY maribavir for the Treatment of Adults With Posttransplant Cytomegalovirus CMV Refractory to Prior Therapies

Takeda Announces China NMPA Approval of LIVTENCITY maribavir for the Treatment of Adults With Posttransplant Cytomegalovirus CMV Refractory to Prior Therapies

Related Keywords

China ,Japan ,Canada ,Massachusetts ,United States ,Australia ,Osaka ,Ramona Sequeira ,Clin Virol ,European Commission ,Exchange Commission ,International Media ,Takeda Pharmaceutical Company Limited ,National Medical Products Administration ,Global Portfolio Division ,European Union ,Therapeutic Goods Administration ,Health Canada ,China Center ,Only Inhibitor ,Kinase Approved ,Adults With Post Transplant ,Demonstrating Maribavir Was Superior ,Conventional Therapies ,Most Common ,Serious Post Transplant Infections ,Can Lead ,Transplanted Organ ,Breakthrough Therapy Designation ,Drug Evaluation ,Study Week ,Products Characteristics ,Annual Report ,Oncol Stem Cell ,Goods Administration ,Published October ,Sao Paolo ,Media Contact ,Takeda Pharmaceutical Company Limited China Nmpa Livtencity Maribavir Treatment Cytomegalovirus Cmv Ul97 Infection National Medical Products Administration Stem Cell Transplant Hsct Solid Organ Sot Ganciclovir Valganciclovir Cidofovir Foscarnet Center For Drug Evaluation Ramona Sequeira Beta Herpesvirus ,